Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MASP2 | O00187 | 1/20 | 0.92 |
| ▸ | SCN2A | Q99250 | 5/20 | 0.57 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.57 |
| ▸ | LTA4H | P09960 | 1/20 | 0.56 |
| ▸ | HPGDS | O60760 | 2/20 | 0.49 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.47 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.47 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL725351 | 0.96 | MASP2 (1.00) | MASP2SCN2ANPY5RLTA4HHPGDS | |
| SCHEMBL4244858 | 0.84 | MASP2 (0.71) | MASP2SCN2ANPY5RLTA4HHPGDS | |
| SCHEMBL4053949 | 0.83 | MASP2 (0.70) | MASP2SCN2ANPY5RLTA4HSCN9A | |
| Hydrochloric Acid SCHEMBL4243690 | 0.83 | MASP2 (0.69) | MASP2SCN2ANPY5RLTA4HHPGDS | |
| SCHEMBL10979 | 0.82 | MASP2 (0.68) | MASP2SCN2ANPY5RLTA4HSCN9A | |
| Hydrochloric Acid SCHEMBL4061012 | 0.82 | MASP2 (0.68) | MASP2SCN2ANPY5RLTA4HSCN9A | |
| Trifluoroacetic Acid SCHEMBL16566514 | 0.81 | MASP2 (0.72) | MASP2SCN2ANPY5RLTA4HHPGDS | |
| SCHEMBL13665045 | 0.81 | MASP2 (0.72) | MASP2SCN2ANPY5RLTA4HHPGDS | |
| SCHEMBL18130901 | 0.80 | MASP2 (0.66) | MASP2SCN2ANPY5RLTA4HSCN9A | |
| SCHEMBL20169742 | 0.80 | MASP2 (0.66) | MASP2SCN2ANPY5RLTA4HHPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090270475-A1 | INHIBITION OF BACTERIAL BIOFILMS WITH IMIDAZOLE-PHENYL DERIVATIVES | NORTH CAROLINA STATE UNIVERSITY (US) | 2009-10-29 | — | — | US | disclosed |
| WO-2009123753-A1 | INHIBITION OF BACTERIAL BIOFILMS WITH IMIDAZOLE-PHENYL DERIVATIVES | NORTH CAROLINA STATE UNIVERSITY (US) | 2009-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270475-A1 | INHIBITION OF BACTERIAL BIOFILMS WITH IMIDAZOLE-PHENYL DERIVATIVES | TFPI, O60361, PGLS | MASP2 774/4885SCN2A 3744/4885NPY5R 4189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.